)
Hyderabad-based pharmaceutical major Dr Reddy’s Laboratories has launched Paricalcitol capsules, a therapeutic equivalent generic version of Zemplar (Paricalcitol) capsules in the US market.
The capsules were launched following the approval by the United States Food & Drug Administration, a company release stated on Wednesday.
The Zemplar brand and generic had US sales of approximately $109.6 million for the most recent 12 months ending in March 2014, according to IMS Health.
Dr Reddy’s capsules 1 mcg, 2 mcg and 4 mcg are available in bottle counts of 30.
